Literature DB >> 19139888

Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches.

Terry J Fry1, Jessica L Shand, Matthew Milliron, Sarah K Tasian, Crystal L Mackall.   

Abstract

Dendritic cells (DCs) serve as central regulators of adaptive immunity by presenting antigens and providing necessary co-signals. Environmental information received by the DCs determines the co-signals delivered to the responding adaptive cells and, ultimately, the outcome of the interaction. DCs loaded with relevant antigens have been used as therapeutic cellular vaccines, but the optimal antigen loading method has not been determined. We compared different methods to load class I and class II epitopes from the male antigenic complex, HY, onto DCs for the potency of the immune response induced in vivo. Co-incubation of female DCs with HY peptides, RNA or cell lysate from HY expressing tumor induced immune responses equivalent to male DCs. In contrast, female DCs incubated with irradiated, apoptotic HY expressing tumor cells (or male B cells) generated a stronger immune response than male DCs or female DCs loaded using any of the other methods. DC loading with apoptotic tumor resulted in complete protection against high dose HY-expressing tumor challenge whereas 100% lethality was observed in groups receiving DCs that were loaded with peptides, RNA, or lysate. We conclude that signals provided to the DCs by apoptotic cells substantially augment the potency of DC vaccines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19139888      PMCID: PMC2791794          DOI: 10.1007/s00262-008-0638-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  28 in total

Review 1.  Dendritic cells: specialized and regulated antigen processing machines.

Authors:  I Mellman; R M Steinman
Journal:  Cell       Date:  2001-08-10       Impact factor: 41.582

Review 2.  Exploiting dendritic cells to improve vaccine efficacy.

Authors:  Ralph M Steinman; Melissa Pope
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

Review 3.  Manipulating dendritic cell biology for the active immunotherapy of cancer.

Authors:  David W O'Neill; Sylvia Adams; Nina Bhardwaj
Journal:  Blood       Date:  2004-07-01       Impact factor: 22.113

Review 4.  Toll-like receptor control of the adaptive immune responses.

Authors:  Akiko Iwasaki; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

5.  Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8(+) T cells produce active immune unresponsiveness.

Authors:  Thomas A Ferguson; John Herndon; Bennett Elzey; Thomas S Griffith; Steve Schoenberger; Douglas R Green
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

6.  Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells.

Authors:  Anna K Nowak; Richard A Lake; Amanda L Marzo; Bernadette Scott; William R Heath; Edward J Collins; Jeffrey A Frelinger; Bruce W S Robinson
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

7.  Escape from immune surveillance does not result in tolerance to tumor-associated antigens.

Authors:  Fraia Melchionda; Melissa K McKirdy; Filomena Medeiros; Terry J Fry; Crystal L Mackall
Journal:  J Immunother       Date:  2004 Sep-Oct       Impact factor: 4.456

8.  Cancer immunotherapy: moving beyond current vaccines.

Authors:  Steven A Rosenberg; James C Yang; Nicholas P Restifo
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

9.  Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis.

Authors:  Ulrich E Schaible; Florian Winau; Peter A Sieling; Karsten Fischer; Helen L Collins; Kristine Hagens; Robert L Modlin; Volker Brinkmann; Stefan H E Kaufmann
Journal:  Nat Med       Date:  2003-07-20       Impact factor: 53.440

10.  Immune tolerance after delivery of dying cells to dendritic cells in situ.

Authors:  Kang Liu; Tomonori Iyoda; Marzena Saternus; Yukino Kimura; Kayo Inaba; Ralph M Steinman
Journal:  J Exp Med       Date:  2002-10-21       Impact factor: 14.307

View more
  19 in total

Review 1.  Concise Review: Mechanisms Behind Apoptotic Cell-Based Therapies Against Transplant Rejection and Graft versus Host Disease.

Authors:  Adrian E Morelli; Adriana T Larregina
Journal:  Stem Cells       Date:  2016-02-29       Impact factor: 6.277

2.  Extracorporeal photopheresis attenuates murine graft-versus-host disease via bone marrow-derived interleukin-10 and preserves responses to dendritic cell vaccination.

Authors:  Christian M Capitini; Jessica P E Davis; Shannon M Larabee; Sarah Herby; Nicole M Nasholm; Terry J Fry
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-07       Impact factor: 5.742

3.  Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy.

Authors:  Joanna L Meadors; Yonghzi Cui; Qing-Rong Chen; Young K Song; Javed Khan; Glenn Merlino; Maria Tsokos; Rimas J Orentas; Crystal L Mackall
Journal:  Pediatr Blood Cancer       Date:  2011-04-01       Impact factor: 3.167

Review 4.  Extracorporeal photopheresis-induced immune tolerance: a focus on modulation of antigen-presenting cells and induction of regulatory T cells by apoptotic cells.

Authors:  Chang-Qing Xia; Kim A Campbell; Michael J Clare-Salzler
Journal:  Curr Opin Organ Transplant       Date:  2009-08       Impact factor: 2.640

5.  Methionine enkephalin (MENK) improved the functions of bone marrow-derived dendritic cells (BMDCs) loaded with antigen.

Authors:  Weiwei Li; Jingjuan Meng; Xuan Li; Hui Hua; Meng Yiming; Qiushi Wang; Enhua Wang; Fengping Shan
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

6.  Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.

Authors:  M R Newton; E J Askeland; E D Andresen; V A Chehval; X Wang; R W Askeland; M A O'Donnell; Y Luo
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

7.  A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines.

Authors:  Renee N Donahue; Brynn B Duncan; Terry J Fry; Barry Jones; William W Bachovchin; Christopher P Kiritsy; Jack H Lai; Wengen Wu; Peng Zhao; Yuxin Liu; Kwong-Yok Tsang; James W Hodge
Journal:  Vaccine       Date:  2014-04-13       Impact factor: 3.641

8.  Minor antigen distribution predicts site-specific graft-versus-tumor activity of adoptively transferred, minor antigen-specific CD8 T Cells.

Authors:  Jessica C Shand; Haiying Qin; Nicole Nasholm; Christian M Capitini; Terry J Fry
Journal:  Biol Blood Marrow Transplant       Date:  2013-10-17       Impact factor: 5.742

9.  Bone marrow deficient in IFN-{gamma} signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect.

Authors:  Christian M Capitini; Sarah Herby; Matthew Milliron; Miriam R Anver; Crystal L Mackall; Terry J Fry
Journal:  Blood       Date:  2009-03-03       Impact factor: 22.113

10.  Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?

Authors:  Laetitia Cicchelero; Sofie Denies; Bert Devriendt; Hilde de Rooster; Niek N Sanders
Journal:  Oncoimmunology       Date:  2015-06-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.